Journal Club 2026

Next HOPA Journal Club

Tuesday, May 19, 2026 at 2 p.m. Central Time

Listen to critical evaluations of hematology/oncology pharmacy publications presented by PGY2 Oncology Residents.

Orange button that says click here to register

The moderator for May's Journal Club session is:

Michael Singel, PharmD, BCPS, BCOP, Johns Hopkins Hospital, Baltimore, MD

May's Journal Club presenters include:

Michael Akon, PharmD

PGY2 Oncology Pharmacy Resident

Hospital of the University of Pennsylvania, Philadelphia, PA

Article:

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Skyler Maclean, PharmD

PGY2 Oncology Pharmacy Resident

M Health Fairview, Cannon Falls, MN

Article:

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer

Featured Articles

An oncology pharmacist helping a patient

Advocacy

Oncology Pharmacist Survey: Understanding Task Value and Professional Satisfaction

April 16, 2026

Recent publications have explored workload and productivity to improve oncology pharmacy practice. HOPA aimed to build upon that research by assessing task valuation.

Membership

Oncology Pharmacist Day: Celebrating the People Who Make the Profession

April 01, 2026

On April 3, 2026, the oncology pharmacy community will mark the first-ever Oncology Pharmacist Day, a new annual observance recognizing the essential role hematology/oncology pharmacists play in improving the lives of people affected by cancer.

HOPA News

Late-Breaking HOPA News: Redefining Relapse: What MajesTEC-3 Means for the Treatment of Multiple Myeloma

March 17, 2026

Sanja Zepcan, PharmD, BCPS, BCOP, and Emily Rux, PharmD, BCOP, discuss the clinical questions raised by the recent MajesTEC-3 trial and the potential changes it finds in the treatment of multiple myeloma.